Supplementary Figure 4 from Expression Profile of BCL-2, BCL-X&lt;sub&gt;L&lt;/sub&gt;, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models